Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 272

1.

Insulin lispro in CSII: results of a double-blind crossover study.

Zinman B, Tildesley H, Chiasson JL, Tsui E, Strack T.

Diabetes. 1997 Mar;46(3):440-3. Erratum in: Diabetes 1997 Jul;46(7):1239.

PMID:
9032100
2.

Counterregulatory hormone responses after long-term continuous subcutaneous insulin infusion with lispro insulin.

Tsui EY, Chiasson JL, Tildesley H, Barnie A, Simkins S, Strack T, Zinman B.

Diabetes Care. 1998 Jan;21(1):93-6.

PMID:
9538976
3.

Preprandial combination of lispro and NPH insulin improves overall blood glucose control in type 1 diabetic patients: a multicenter randomized crossover trial.

Annuzzi G, Del Prato S, Arcari R, Bellomo Damato A, Benzi L, Bruttomesso D, Calderini MC, Coscelli C, Fedele D, Galluzzo A, Giordano M, Giorgino R, Lapolla A, Orsini P, Pagano G, Santoro D, Riccardi G.

Nutr Metab Cardiovasc Dis. 2001 Jun;11(3):168-75.

PMID:
11590992
4.

Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.

Pampanelli S, Torlone E, Ialli C, Del Sindaco P, Ciofetta M, Lepore M, Bartocci L, Brunetti P, Bolli GB.

Diabetes Care. 1995 Nov;18(11):1452-9.

PMID:
8722069
5.

Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents.

Holcombe JH, Zalani S, Arora VK, Mast CJ; Lispro in Adolescents Study Group..

Clin Ther. 2002 Apr;24(4):629-38.

PMID:
12017407
8.

Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group.

Renner R, Pfützner A, Trautmann M, Harzer O, Sauter K, Landgraf R.

Diabetes Care. 1999 May;22(5):784-8.

9.

Effect of continuous subcutaneous insulin infusion with lispro on hepatic responsiveness to glucagon in type 1 diabetes.

Launay B, Zinman B, Tildesley HD, Strack T, Chiasson JL.

Diabetes Care. 1998 Oct;21(10):1627-31.

PMID:
9773721
11.
13.
14.

Optimal provision of daytime NPH insulin in patients using the insulin analog lispro.

Ahmed AB, Home PD.

Diabetes Care. 1998 Oct;21(10):1707-13.

PMID:
9773735
15.
16.

Optimization of evening insulin dose in patients using the short-acting insulin analog lispro.

Ahmed AB, Mallias J, Home PD.

Diabetes Care. 1998 Jul;21(7):1162-6.

PMID:
9653613
17.

Insulin lispro lowers postprandial glucose in prepubertal children with diabetes.

Deeb LC, Holcombe JH, Brunelle R, Zalani S, Brink S, Jenner M, Kitson H, Perlman K, Spencer M.

Pediatrics. 2001 Nov;108(5):1175-9.

PMID:
11694699
18.

Cessation of insulin infusion at night-time during CSII-therapy: comparison of regular human insulin and insulin lispro.

Reichel A, Rietzsch H, Köhler HJ, Pfützner A, Gudat U, Schulze J.

Exp Clin Endocrinol Diabetes. 1998;106(3):168-72.

PMID:
9710355
20.

Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group.

Anderson JH Jr, Brunelle RL, Keohane P, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R.

Arch Intern Med. 1997 Jun 9;157(11):1249-55.

PMID:
9183237
Items per page

Supplemental Content

Support Center